<?xml version="1.0" encoding="UTF-8"?>
<p>Immunoprophylaxis is the most effective strategy for the prevention of influenza infection. Inactivated vaccines have efficacy rates from 70% to 90%. Currently, the inactivated vaccine is recommended for all children older than 6 months of age with high risk conditions including chronic pulmonary or cardiac disease, immunosuppressive disorders, sickle cell disease and other hemoglobinopathies, diseases requiring long-term aspirin therapy, chronic metabolic and renal diseases; healthy children aged 6–23 months; and household contacts over the age of 6 months of high risk persons. A live, attenuated influenza vaccine was licensed in 2003. It is administered by the intranasal route and is approved for healthy children aged 5–17 years. 
 <boxed-text position="float" id="Sb13_25">
  <p>Although antiviral medications may attenuate the course of influenza when given early, immunoprophylaxis with vaccines is the most effective strategy for the control of influenza infections.</p>
 </boxed-text>
</p>
